alendronate(redirected from Binosto)
Also found in: Dictionary, Thesaurus.
alendronate/alen·dro·nate/ (ah-len´dro-nāt) a bisphosphonate calcium-regulating agent used in the form of the sodium salt to inhibit the resorption of bone in the treatment of osteitis deformans, osteoporosis, and hypercalcemia related to malignancy.
A bisphosphonate drug, C4H13NO7P2, that inhibits bone resorption and is used in the form of its sodium salt to treat and prevent osteoporosis in postmenopausal women.
a bone-resorption inhibitor.
indications This drug is used to treat osteoporosis in postmenopausal women and Paget's disease.
contraindication Known hypersensitivity to biphosphonates prohibits the use of this drug.
adverse effects Side effects include anemia, hypokalemia, hypomagnesemia, hypophosphatemia, osteonecrosis of the jaw, abdominal pain, anorexia, constipation, nausea, vomiting, bone pain, hypertension, urinary tract infection, and fluid overload.
alendronateA biphosphonate used to treat postmenopausal osteoporosis and Paget’s disease of bone. Alendronate reduces vertebral fractures by 48% and other fractures by 21%, increases bone density by 9% and density of the hip bones by 6% over 3 years of therapy.
Nausea, stomach pain, constipation, diarrhoea, bloating, headaches, dizziness, swelling of joints (especially of hands and feet).
Mechanism of action
Marked inhibition of bone resorption by inhibiting osteoclastic activity and number of osteoclasts by reducing recruitment, and increasing apoptosis.
alendronateFosamax® Endocrinology A biphosphonate used to treat postmenopausal osteoporosis and Paget's disease of bone. See Osteoporosis. Cf Salmon calcitonin.
alendronateA drug used in the prevention and treatment of post-menopausal OSTEOPOROSIS. A brand name is Fosamax.
A nonhormonal drug used to treat osteoporosis in postmenopausal women.
Mentioned in: Osteoporosis
A bisphosphonate drug used to treat osteoporosis.
[coined term based on parts of the chemical name]